Yang Xiang to Immunotherapy
This is a "connection" page, showing publications Yang Xiang has written about Immunotherapy.
Connection Strength
1.276
-
Chen L, Huang L, Gu Y, Li C, Sun P, Xiang Y. Novel post-translational modifications of protein by metabolites with immune responses and immune-related molecules in cancer immunotherapy. Int J Biol Macromol. 2024 Oct; 277(Pt 1):133883.
Score: 0.721
-
He SQ, Huang Y, Zhao ZY, Wen SQ, Lv SH, Wang L, Bei WX, Xiang YQ, Liu GY. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study. Br J Cancer. 2026 Feb; 134(4):598-607.
Score: 0.199
-
He SQ, Liu GY, Yu YH, Wang L, Zhang GY, Peng DS, Bei WX, Chen CL, Lv SH, Zhao ZY, Huang Y, Xiang YQ. Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study. Oral Oncol. 2024 Dec; 159:107074.
Score: 0.183
-
Jiang F, Mao M, Jiang S, Jiao Y, Cao D, Xiang Y. PD-1 and TIGIT coexpressing CD8?+?CD103?+?tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy. Int Immunopharmacol. 2024 Jan 25; 127:111381.
Score: 0.173